1. Signaling Pathways
  2. GPCR/G Protein
  3. P2Y Receptor
  4. P2Y Receptor Isoform
  5. P2Y Receptor Antagonist

P2Y Receptor Antagonist

P2Y Receptor Antagonists (32):

Cat. No. Product Name Effect Purity
  • HY-110322
    PPTN hydrochloride
    Antagonist 99.89%
    PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity.
  • HY-108672
    NF157
    Antagonist 99.13%
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively. NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA).
  • HY-101308A
    MRS2179 tetrasodium hydrate
    Antagonist 99.60%
    MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors. MRS2179 tetrasodium hydrate inhibits platelet aggregation.
  • HY-124405
    P2Y1 antagonist 6
    Antagonist
    P2Y1 antagonist 6 (Example 30) is a P2Y1 receptor (P2Y1 Receptor) antagonist and can be used in antithrombotic research.
  • HY-179448
    P2Y2R antagonist 1
    Antagonist
    P2Y2R antagonist 1 is a selective P2Y2R antagonist (pIC50 = 7.78). P2Y2R antagonist 1 can be used for the study of Glioma.
  • HY-137955
    MRS 2211 sodium hydrate
    Antagonist
    MRS 2211 sodium hydrate is a competitive P2Y13 receptor antagonist (pIC50= 5.97). MRS 2211 sodium hydrate is highly selective to the P2Y13 receptor, showing more than 20-fold selectivity compared to the P2Y1 and P2Y12 receptors. MRS 2211 sodium hydrate can be used to further investigate the role of the P2Y13 receptor in different physiological and pathological processes, such as its function in blood cells, the nervous system and the immune system.
  • HY-108658
    MRS2500 tetraammonium
    Antagonist 99.91%
    MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (Ki=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Antithrombotic activity.
  • HY-109122
    Selatogrel
    Antagonist 99.75%
    Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy.
  • HY-172417
    Becondogrel
    Antagonist 99.39%
    Becondogrel (2-Oxoclopidogrel) is the metabolite of Clopidogrel (HY-15283). Becondogrel irreversibly inhibits P2Y12 receptor, thereby inhibiting platelet aggregation and thrombosis.
  • HY-115273A
    MRS 2179 ammonium
    Antagonist 99.34%
    MRS 2179 ammonium is a selective and competitive antagonist for P2Y1 receptor, with KB of 0.177 μM.
  • HY-137626A
    Sp-ATPαS tetrasodium solution (100mM)
    Antagonist 98.60%
    Sp-ATPαS tetrasodium is a thiophosphonate analogue of ATP. Sp-ATPαS tetrasodium is a competitive antagonist of the human P2Y1 receptor and can inhibit the calcium signal induced by ADP. Sp-ATPαS tetrasodium has higher metabolic stability than ATP. Sp-ATPαS tetrasodium can be used to study the binding mode of metal-nucleotide in enzymatic reactions.
  • HY-172181
    NSC380324
    Antagonist
    NSC380324 is a P2Y12 receptor antagonist, possessing antiplatelet activity, and can be utilized in research on atherosclerotic cardiovascular diseases.
  • HY-103064
    2-Methylthio-AMP sodium
    Antagonist
    2-Methylthio-AMP sodium is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP sodium is an inhibitor of ADP-dependent platelet aggregation.
  • HY-12435
    SAR216471
    Antagonist
    SAR216471 is a P2Y12 receptor antagonist. SAR216471 reversibly blocks the binding of 2MeSADP to P2Y12 receptors in vitro with an IC50 of 17 nM. SAR216471 can result in the inhibition of platelet aggregation. SAR216471 exhibits anti-thrombotic activity in rat model. SAR216471 can be studied in research on thrombosis.
  • HY-168139
    MRS4865
    Antagonist
    MRS4865 (compund 7a) is a chimera of a P2Y14 receptor antagonist and a UDP-glucose agonist that protects against neuropathic pain.
  • HY-103055
    PPTN mesylate
    Antagonist
    PPTN mesylate is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN mesylate exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity.
  • HY-117572
    MRS2567
    Antagonist
    MRS2567 is a P2Y receptor antagonist with the activity of inhibiting contraction of mouse mesenteric arteries. MRS2567 can inhibit the sustained contraction caused by UTP and UDP, and inhibit the Na+, K+, 2Cl- co-transport-dependent signaling pathway, thereby affecting the myogenic tone of mouse mesenteric arteries.
  • HY-174126
    P2Y1 antagonist 2
    Antagonist
    P2Y1 antagonist 2 (Compound 19) is a P2Y1 receptor antagonist (IC50: 0.49 μM). P2Y1 antagonist 2 has significant antiplatelet aggregation activity and exerts its effects by inhibiting P2Y1 receptor. P2Y1 antagonist 2 can upregulate nuclear Nrf2 protein levels, exhibit neuroprotective effects, and resist oxidative stress damage. P2Y1 antagonist 2 can effectively reduce cerebral infarction area and improve neurobehavioral function, and can be used in the study of ischemic stroke.
  • HY-122048
    AR-C67085
    Antagonist
    AR-C67085 (PSB 0413; FPL 67085) is a potent platelet P2T receptor antagonist with an pIC50 value of 8.60. AR-C67085 inhibits ADP-induced platelet aggregation.
  • HY-174127
    P2Y1 antagonist 3
    Antagonist
    P2Y1 antagonist 3 (compound 36b) is a blood-brain barrier (BBB)-penetrant P2Y1 antagonist with an IC50 of 0.50 μM. P2Y1 antagonist 3 exhibits protective effects in a rat middle cerebral artery occlusion (MCAO) model and demonstrates neuroprotective activity against oxidative stress by upregulating nuclear Nrf2 protein levels.